3.2. Alpelisib, a PI3K Inhibitor, in Combination with Eribulin Synergistically Inhibits the Proliferation of Paclitaxel-Sensitive and Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer Cells. Here, PIK3CG is linked to endometrial cancer.